Zobrazeno 1 - 10
of 95
pro vyhledávání: ''
Publikováno v:
American Journal of Clinical Oncology. 44:158-161
Objective The objective of this study was to review real-world patterns of chemotherapy utilization among patients with metastatic gastric/lower esophageal adenocarcinoma with particular focus on the use of ramucirumab plus paclitaxel in previously t
Autor:
Haji Chalchal, Nicholas Chandna, Michael A. J. Moser, John Shaw, Shahid Ahmed, Kamal Haider, Adnan Zaidi, Gopinath Narasimhan
Publikováno v:
American Journal of Clinical Oncology. 44:93-98
Limited evidence is available regarding the survival benefit of second-line therapy in real world patients with advanced biliary tract and gallbladder cancer. Until very recently, there was a lack of randomized clinical trials to address this importa
Autor:
Jennifer Renaud, Rimini Breakstone, Ashlee Sturtevant, Kevin P. Charpentier, Lindsey Cavanaugh, Adam J. Olszewski, Kara L. Leonard, Alexander G Raufi, Howard Safran, Khaldoun Almhanna, Rachel E. Beard, Kelsey MacKinnon
Publikováno v:
American Journal of Clinical Oncology. 43:857-860
Objectives Multiple clinical trials have established a role for adjuvant chemotherapy for patients with pancreatic ductal adenocarcinoma. Adjuvant FOLFIRINOX increases survival as compared with gemcitabine but with increased toxicity. FOLFOX+nab-pacl
Autor:
Hyo Soung Cha, Jinkook Kim, Jaihwan Kim, Jin-Hyeok Hwang, Jin Won Kim, Sang Myung Woo, Dong Woo Shin, Se Yeol Yang, Jong-Chan Lee, Min Jae Kim, Ji Won Kim, Woojin Lee, Philiip Park
Publikováno v:
American Journal of Clinical Oncology. 43:654-659
Objective By using the Korean Pancreatic Cancer (K-PaC) registry, we compared the clinical outcomes of FOLFIRINOX (FFX) and gemcitabine plus nab-paclitaxel (GNP) in patients with metastatic pancreatic cancer (MPC). Methods We constructed a web-based
Autor:
Hao Xie, Tanios Bekaii-Saab, Joleen M. Hubbard, Aminah Jatoi, Robert R. McWilliams, John R. Ogden, Jun Yin, Wen Wee Ma, Gloria M. Petersen, Amit Mahipal, Junjia Liu
Publikováno v:
Am J Clin Oncol
OBJECTIVES Survival benefit of combination over single-agent chemotherapy for metastatic pancreatic ductal adenocarcinoma (PDAC) was demonstrated in younger patients in clinical trials. The authors aimed to evaluate whether this survival benefit of c
Autor:
Asad Javed, Svetomir N. Markovic, Lori A. Erickson, Vera J. Suman, Marc S. Ernstoff, Daniel M. Anderson, Darci J. Wall, Joel M. Reid
Publikováno v:
American Journal of Clinical Oncology. 43:115-121
Objectives With the introduction of novel immune therapeutics for the treatment of disseminated malignancies, we sought to evaluate whether deliberate sequencing of immunotherapy before/after conventional cytotoxic chemotherapy would have an impact o
Autor:
Jennifer L. Spratlin, Erica S Tsang, Yuan Xu, Winson Y. Cheung, Sharlene Gill, Shiying Kong, Christina Kim
Publikováno v:
American Journal of Clinical Oncology. 42:903-908
OBJECTIVES Limited evidence exists for chemotherapy selection in advanced pancreatic cancer (APC) after first-line FOLFIRINOX. Second-line gemcitabine/nab-paclitaxel (GEMNAB) is publicly funded in the Canadian provinces of Alberta (AB) and Manitoba (
Autor:
James C. Padussis, Jane L. Meza, Quan P. Ly, Michael A. Hollingsworth, Chandrakanth Are, Audrey J. Lazenby, Vivek Verma, Chi Lin, Madi Madiyalakan, Christopher F. Nicodemus, Lyudmyla Berim, Jean L. Grem, James K. Schwarz
Publikováno v:
Am J Clin Oncol
Objective Cancer antigen (CA)-125 influences progression, metastasis, and outcomes in pancreatic cancer. This phase I/II trial (NCT01959672) evaluated the safety, efficacy, and immunologic correlates of chemoimmunotherapy (CIT) with oregovomab (anti-
Autor:
Mi Hyun Kim, Tae-Won Jang, Min Ki Lee, Kyeong Choel Shin, Choonhee Son, Hyun Kyung Lee, Hyun-Kuk Kim, Jung Seop Eom, Jiyeon Roh, Seong Hoon Yoon, Shin Yup Lee, Jehun Kim
Publikováno v:
American journal of clinical oncology. 44(7)
Objectives Immune checkpoint inhibitors (ICIs) targeting the programmed cell death receptor-1 and its ligand have achieved impressive success in treating patients with advanced-stage non-small cell lung cancer (NSCLC) after failed first-line cytotoxi
Autor:
Panteleimon Kountourakis, Athanasios Petrou, Dimitrios Schizas, Nikolaos Dimitrokallis, Dimitrios Oikonomou, Michalis V. Karamouzis, Georgios Astras, Demetris Papamichael, Spyridon Davakis, Alexandros Papalampros, Dimitrios Moris, Evangelos Felekouras
Publikováno v:
American journal of clinical oncology. 44(7)
Objectives Locally advanced pancreatic cancer (LAPC) is found in about 40% of patients with pancreatic cancer. Irreversible electroporation (IRE) is a nonthermal ablative technique that provides an alternative in patients with LAPC and can be safely